These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 27492610)
21. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. Bahouth Z; Halachmi S; Moskovitz B; Nativ O Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756 [TBL] [Abstract][Full Text] [Related]
23. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Witjes JA; Hendricksen K Eur Urol; 2008 Jan; 53(1):45-52. PubMed ID: 17719169 [TBL] [Abstract][Full Text] [Related]
24. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. Crijnen J; De Reijke TM Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950 [TBL] [Abstract][Full Text] [Related]
25. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890 [TBL] [Abstract][Full Text] [Related]
26. Update on intravesical agents for non-muscle-invasive bladder cancer. Shariat SF; Chade DC; Karakiewicz PI; Scherr DS; Dalbagni G Immunotherapy; 2010 May; 2(3):381-92. PubMed ID: 20635902 [TBL] [Abstract][Full Text] [Related]
27. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
28. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Hendricksen K; Witjes JA Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630 [TBL] [Abstract][Full Text] [Related]
30. Tackling non-muscle invasive bladder cancer in the clinic. Woldu SL; Şanli Ö; Lotan Y Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179 [TBL] [Abstract][Full Text] [Related]
31. [Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy]. Irani J Prog Urol; 2016 Nov; 26(14):860-864. PubMed ID: 27712914 [TBL] [Abstract][Full Text] [Related]
32. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. Mangiarotti B; Trinchieri A; Del Nero A; Montanari E Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434 [TBL] [Abstract][Full Text] [Related]
33. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448 [TBL] [Abstract][Full Text] [Related]
34. Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Barlow LJ; Benson MC Curr Urol Rep; 2013 Apr; 14(2):65-70. PubMed ID: 23378162 [TBL] [Abstract][Full Text] [Related]
35. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology. Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM; Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824 [TBL] [Abstract][Full Text] [Related]
36. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. Steinberg RL; Thomas LJ; Nepple KG Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115 [TBL] [Abstract][Full Text] [Related]
38. Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-Does it complicate surgery and adversely impact oncological outcome? Sri D; Lee HJ; El-Gemmal S; Backhouse C; Tay A; John B; Perry MJ; Ayres BE; Issa R Urol Oncol; 2021 May; 39(5):300.e15-300.e20. PubMed ID: 33032922 [TBL] [Abstract][Full Text] [Related]
39. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445 [TBL] [Abstract][Full Text] [Related]
40. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]